The calpain inhibitor A-705253 attenuates alcohol-seeking and relapse with low side-effect profile

Preclinical studies revealed contribution of N-methyl-D-aspartate receptors (NMDARs) to a variety of neuropsychiatric diseases including alcoholism, but development of NMDAR antagonists for therapeutic use has been a challenge, in part due to severe side effects. One of the key intracellular events...

Full description

Saved in:
Bibliographic Details
Main Authors: Vengeliene, Valentina (Author) , Sommer, Wolfgang H. (Author) , Spanagel, Rainer (Author)
Format: Article (Journal)
Language:English
Published: 2016
In: Neuropsychopharmacology
Year: 2015, Volume: 41, Issue: 4, Pages: 979-988
ISSN:1740-634X
DOI:10.1038/npp.2015.225
Online Access:Verlag, Volltext: https://doi.org/10.1038/npp.2015.225
Verlag, Volltext: https://www-nature-com.ezproxy.medma.uni-heidelberg.de/articles/npp2015225
Get full text
Author Notes:Valentina Vengeliene, Achim Moeller, Marcus W. Meinhardt, Patrick M. Beardsley, Wolfgang H. Sommer, Rainer Spanagel and Anton Bespalov
Description
Summary:Preclinical studies revealed contribution of N-methyl-D-aspartate receptors (NMDARs) to a variety of neuropsychiatric diseases including alcoholism, but development of NMDAR antagonists for therapeutic use has been a challenge, in part due to severe side effects. One of the key intracellular events resulting from stimulation of NMDAR is activation of calpains-calcium-dependent cysteine proteases. Here we studied whether inhibition of calpains would produce therapeutic-like effects of NMDAR antagonists but without their NMDAR-mediated side-effect profile. The calpain inhibitor A-705253 (3-10 mg/kg) was tested in a model of cue-induced reinstatement of alcohol-seeking behavior in post-dependent Wistar rats and in an alcohol deprivation effect (ADE) model in long-term alcohol drinking Wistar rats, two behavioral models for alcohol-seeking and relapse, respectively. We also tested the effect of A-705253 on the saccharine deprivation effect (SDE) as a selectivity measure. Acute treatment with A-705253 dose-dependently reduced cue-induced reinstatement of alcohol-seeking behavior. Repeated administration of A-705253 caused significant reductions of relapse-like excessive alcohol intake during the post-abstinence drinking days, an effect that persisted during two more successive drug-free drinking weeks, which was selective for the ADE as the SDE was unaffected. However, A-705253 did not produce psychostimulant, cognition impairing (delayed-matching-to-position), or psychotomimetic effects (specifically, phencyclidine discriminative stimulus effects). Taken together, these results demonstrate the involvement of calpains in alcohol-seeking and relapse and present a rationale for a novel pharmacological intervention that may reduce craving and relapse with minimal side effects in alcohol-dependent patients.
Item Description:Gesehen am 27.03.2019
Published online 16 September 2015
Physical Description:Online Resource
ISSN:1740-634X
DOI:10.1038/npp.2015.225